Refractory Adult Acute Myeloid Leukemia Completed Phase 1 Trials for Merestinib (DB12381)

IndicationStatusPhase
DBCOND0090924 (Refractory Adult Acute Myeloid Leukemia)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03125239Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaTreatment